Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day
(WorldNews Health)

Company aspires to exceed $2 billion in revenue with 27%-30% adjusted EBITDA margin by year end 2024 GAITHERSBURG, Md., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today outlined its growth strategy over the next five years and announced its 2024 financial and operational goals during the company`s Analyst and Investor Day held in New York City. Emergent`s senior management shared their vision for continuing to build leadership positions in select public health threat markets and contract development and manufacturing (CDMO), leveraging the company`s unique set of assets, and realizing sustained financial performance and shareholder value creation. Robert G....